Extended Data Fig. 3: Time to metastasis analysis of genomic metrics.
From: Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer
(A) Participants with a high number of events (greater than median, red, n = 50 participants) did not have a significantly shorter time to metastasis than those with fewer events (grey, n = 56 participants). (B) Participants split by the upper tertile of the Spearman metric (red, n = 35 participants) and the lower two tertiles (grey, n = 71 participants). (C) Participants are split by the median mPGA. Participants with high mPGA (red, n = 53 participants) do not have significantly shorter time to metastasis than those with low mPGA (grey, n = 53 participants). (D) Participants are split by the median max PGA. Participants with high max PGA (red, n = 53 participants) do not have significantly shorter time to metastasis than those with low max PGA (grey, n = 53 participants). (E) Participants are split between those that had a subclonal mutation on the driver gene panel (red, n = 38 participants) and those without (grey, n = 57 participants). KMT2C and KMT2D were excluded from this analysis. (F) Participants are split between those with >1 mutated gene on the panel (red, n = 29 participants) and those with 1 or 0 (grey, n = 66 participants). (G) Participants split equally to Fig. 5G. Double heterogeneous participants (red, n = 17 participants) had a significantly shorter time to metastasis than the rest (grey, n = 89 participants, P = 0.0497). P values are calculated using a log-rank test. (H) CPH model, using clinical co-variates and genomic metrics with p < 0.1 in a univariate CPH model, for time to metastasis. (I) Cox proportional hazards (CPH) model, using clinical co-variates and Joint Diversity metric, for time to metastasis. Forest plots show 95% confidence interval of hazard ratios, and the covariate P values, derived from a Wald test (*P < 0.05, **P < 0.01, ***P < 0.001). Hazard ratios for Lossness and Joint Diversity represent the increase in hazard between their 5th and 95th percentile values (within the Sequencing Cohort).
